Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants

NCT04484337 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT04484337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04484337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants
Lead sponsor
ViiV Healthcare
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2020
Completion date
May 5, 2023
Enrollment
138 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections